Evaluation of CA 242 as a Tumor Marker in Gallbladder Cancer

Purpose

Gallbladder and pancreas share common embryological origin, and malignancies of these organs may share common tumor antigens. CA 242 is a tumor marker for pancreatic cancer, but has not been studied in gallbladder cancer (GBC). We measured serum CA 242 levels in patients with GBC and compared it with those in patients with gallstones (GS) and healthy volunteers.

Methods

We enrolled consecutive patients with GBC (cases), GS (disease controls), and healthy volunteers (healthy controls). Serum CA 242, CEA, and CA 19?C9 levels were measured using ELISA. Receiver operator curve was plotted for all the three markers.

Results

We studied 117 patients with GBC, 58 with GS, and 10 healthy volunteers. Among patients with GBC, 81 (69%) also had GB calculi. Patients with GBC more often had elevated CA 242 levels (64%) compared to those with GS (17%; p?<?0.001) and healthy controls (0%; p?<?0.001). The median levels of CA 242 was higher in the GBC group (59 [199] U/ml) compared to the GS group (10 [13] U/ml; p?<?0.001) and the control group (3 [14.5] U/ml; p?<?0.001). The sensitivity, specificity, positive predictive value (PPV), and negative predictive values of CA 242 for diagnosis of GBC were 64%, 83%, 88%, and 53%, respectively. At a cutoff of 45?U/ml, the specificity and PPV increased to 100%. CA 242 had higher AOC (0.759) compared to CEA (0.528) and CA 19?C9 (0.430).

Conclusions

CA 242 is a promising tumor marker for GBC and performs better than CEA and CA 19-9.     

Significance of CA 125 antigen levels in patients with ovarian cancer

CA 125 antigen levels were measured in patients with ovarian cancer (54 cases) by the RIA method using a monoclonal antibody OC 125 and were examined as a marker for ovarian cancer. The upper normal limit of CA 125 of 35 U/ml was derived from the mean value (15.7 U/ml) + 2 SD (9.3 U/ml) of CA 125 in healthy controls. The mean value of CA 125 in patients with ovarian cancer (1160 +/- 1850 U/ml) was statistically (p less than 0.001) higher than those of healthy controls, benign ovarian tumors (28 +/- 20 U/ml) and cervical cancers (226 +/- 526 U/ml). Elevated CA 125 levels were also found in the early stages pregnancy and endometriosis, but these cases did not show such high CA 125 values as those of ovarian cancers. In addition, CA 125 levels were not affected by the menstrual cycle. Among ovarian malignancies, elevated CA 125 values were specifically demonstrated in serous cystadenocarcinoma (positivity 89%) and markedly low in mucinous cystadenocarcinoma (positivity 16%). No positive correlation of CA 125 values with clinical stage (FIGO) were found in any ovarian cancer patients. The rise or fall of CA 125 level was well correlated with the progression or regression observed in cancer patients with positive CA 125 levels. In conclusion, serum CA 125 determinations may be useful in patients with ovarian cancer (except for mucinous type) for diagnosis and for monitoring the results of treatment.     

Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid.

Malignant and nonmalignant serosal fluids have been found to be associated with high serum levels of CA 125, suggesting that the presence of fluid in the serosal cavities may stimulate its release. In this study, we investigated the relationship between serum CA 125 levels and the presence of pleural fluid in patients with chronic heart failure (CHF). We performed a clinical study in 36 patients with CHF with and without pleural fluid. Patients with CHF were divided into two groups based on the presence of fluid in the pleural cavity. Group 1 included 18 CHF patients (6 females, 12 males) with pleural fluid. Group 2 consisted of 18 CHF patients (7 females, 11 males) without pleural fluid. The control group consisted of 30 healthy volunteers (12 females, 18 males). The serum CA 125 level was determined in all groups. Serum CA 125 levels were found to be 100.0 +/- 129.4 U/ml in CHF patients with pleural fluids, whereas they were 36.5 +/- 35.2 U/ml in CHF patients without pleural fluid and 8.9 +/- 6.1 U/ml in the control group. Significantly high serum CA 125 levels were found in CHF patients with pleural fluids (p < 0.05) when compared with both CHF patients without pleural fluid and the control group. There was also a statistically significant difference in CA 125 levels between patients without pleural fluid and the control group (p < 0.05). We concluded that serum CA 125 levels should be interpreted with caution in patients with CHF in the presence of pleural fluid. Invasive procedures to define the etiology of elevated serum CA 125 levels may be unnecessary in this patient group.     

血清CA125测定在妇科疾病中的应用价值

探讨血清ＣＡ１２５抗原测定对卵巢上皮癌等妇科疾病的临床应用价值。方法采用放射免疫法测定２０５例妇科疾病治疗前后血清ＣＡ１２５抗原含量。结果以ＣＡ１２５＞３５Ｕ／ｍｌ为阳性，其阳性率在卵巢上皮癌及子宫腺肌症或子宫内膜异位症分别为８４．６％（１１／１３）和６４％（１６／２５）。１１例血清ＣＡ１２５阳性的卵巢上皮癌患者经有效化疗和手术后，有９例＜３５Ｕ／ｍｌ以下。１６例ＣＡ１２５阳性的子宫腺肌症及子宫内膜异位症患者术后６周后均＜３５Ｕ／ｍｌ。当ＣＡ１２５复升高，预示上述疾病复发。结论血清ＣＡ１２５测定对卵巢上皮癌、子宫肌腺症和子宫内膜异位症的诊断、疗效评价和复发预测具有重要意义。     

Model Based on Alkaline Phosphatase and Gamma- Glutamyltransferase for Gallbladder Cancer Prognosis

Purpose: To evaluate the prognostic value of alkaline phosphatase (ALP) and gamma-glutamyltransferase(GGT) in gallbladder cancer (GBC). Materials and Methods: Serum ALP and GGT levels and clinicopathologicalparameters were retrospectively evaluated in 199 GBC patients. Receiver operating characteristic (ROC) curveanalysis was performed to determine the cut-off values of ALP and GGT. Then, associations with overall survivalwere assessed by multivariate analysis. Based on the significant factors, a prognostic score model was established.Results: By ROC curve analysis, ALP ≥ 210 U/L and GGT ≥ 43 U/L were considered elevated. Overall survivalfor patients with elevated ALP and GGT was significantly worse than for patients within the normal range.Multivariate analysis showed that the elevated ALP, GGT and tumor stage were independent prognostic factors.Giving each positive factor a score of 1, we established a preoperative prognostic score model. Varied outcomeswould be significantly distinguished by the different score groups. By further ROC curve analysis, the simplescore showed great superiority compared with the widely used TNM staging, each of the ALP or GGT alone, ortraditional tumor markers such as CEA, AFP, CA125 and CA199. Conclusions: Elevated ALP and GGT levelswere risk predictors in GBC patients. Our prognostic model provides infomration on varied outcomes of patientsfrom different score groups.     

CA54/61 as a marker for epithelial ovarian cancer.

Using a new one-step, double-determinant enzyme immunoassay, we performed quantitative measurements of a mucin-type glycoprotein antigen (CA54/61) that we recently detected in sera of ovarian carcinoma patients. When the cutoff value was set at 12 units/ml, at which a high diagnostic efficiency was demonstrated [or at 20 units/ml (mean + 3 SD of healthy females)], the positive rates of ovarian serous, mucinous, clear cell, and endometrioid carcinomas were 76% (or 63%), 63% (or 55%), 57% (or 52%), and 50% (or 38%), respectively. Even in mucinous cystadenocarcinoma, more than one-half of the cases were positive, indicating the potential utility of the assay in the diagnosis of mucinous tumors. In sera from patients with benign ovarian tumors, only 9% (or 4%) of the cases were positive, indicating the quite high specificity of this test for ovarian carcinomas. To make a comparison between CA54/61 and CA125, we set the cutoff level of CA125 at 110 units/ml, at which value a high diagnostic efficiency was demonstrated [or at 35 units/ml (mean + 3 SD of healthy females)]. When both CA54/61 and CA125 were assessed in sera from 36 patients with mucinous cystadenocarcinoma, the positive rates of CA54/61 and CA125 were 64% (or 56%) and 36% (or 56%), respectively, suggesting that CA54/61 is of clinical value as a new tumor marker for ovarian cancers, including mucinous tumors.     

血清糖类抗原125和糖类抗原199在卵巢肿瘤诊断中的意义

目的探讨血清糖类抗原125（CA125）和糖类抗原199（CA199）在卵巢肿瘤诊断中的意义。方法采用化学发光法检测2010年1月至2011年12月收治的196例卵巢肿瘤患者（良性肿瘤组140例、交界性肿瘤组13例、恶性肿瘤组43例）和50例健康体检者（对照组）的血清CA125和CA199。比较两种肿瘤标记物单检及联检在卵巢肿瘤诊断中的敏感度和特异度。结果 （1）CA125在卵巢良性肿瘤、交界性肿瘤和恶性肿瘤的表达水平分别为（19.80±13.57）U/ml、（94.59±53.41）U/ml和（759.00±677.26）U/ml,均高于对照组水平（9.94±5.64）U/ml,各组之间差异有统计学意义（P〈0.05）;（2）CA199在卵巢良性肿瘤、交界性肿瘤和恶性肿瘤的表达水平分别为（69.13±72.08）U/ml、（167.70±19.22）U/ml和（184.00±93.26）U/ml,均高于对照组水平（13.42±11.16）U/ml,但各组之间差异无显著意义（P〉0.05）;（3）CA125在卵巢恶性肿瘤诊断中敏感度、特异度为76.7%和90.0%,均高于CA199,两者联合检测并没有明显提高敏感度,反而降低了特异度。结论 CA125可作为卵巢肿瘤诊断的生物指标,而CA199的敏感度和特异度均较低,临床意义不大,两者联合检测并没有比CA125单项检测更具优势。     

Application of Joint Detection of AFP,CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma

Objective: To explore the application of joint detection of serum AFP, CA19-9, CA125 and CEA in identificationand diagnosis of cholangiocarcinoma (CC). Materials and Methods: The levels of serum AFP, CA19-9, CA125and CEA of both 30 patients with CC and 30 patients with hepatocellular carcinoma (HCC) were assessed.Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic effects of single and jointdetection of those 4 kinds of tumor markers for CC. Results: The levels of serum CA19-9, CA125 and CEAin CC patients were higher than that in HCC patients,whereas that of serum AFP was significantly lower s.The area under ROC curve of single detection of serum AFP, CA19-9, CA125 and CEA were 0.05, 0.86, 0.84and 0.83, with the optimal cutoff values of 15.4 ng/ml, 125.1 U/ml, 95.7 U/ml and 25.9 ng/ml, correspondingly,and the percentage correct single diagnosis was <79%. With joint detection, the diagnostic effect of combinedAFP, CA19-9, CA125 and CEA was the highest, with an area under the ROC curve of 0.94 (95%CI 0.88~0.99).Conclusions: Single detection of serum CA19-9, CA125 and EA is not meaningful. The sensitivity, specificity,the rate of correct diagnosis and the area under ROC curve of joint detection of AFP, CA19-9, CA125 and CEAare highest, indicating that the joint detection of these 4 tumor markers is of great importance in the diagnosisof CC.     

Relation between CA125 levels and second-look operation for ovarian cancer

We investigated the relationship between the serum level of CA125 before a second-look operation (SLO) and SLO findings in 196 patients with adenocarcinoma of the ovary. SLO findings were positive in 38 (19.4%) of 196 patients. The positive rate tended to increase with the clinical stage, but SLO findings were positive even in a patient with stage Ia disease. The pre-SLO serum level of CA125 was positive in 11 patients before SLO, SLO findings were positive in 8 of these 11 patients. The highest diagnostic accuracy (37.9%) for the pre-SLO serum level of CA125 was obtained at a cut-off value of 11 U/ml. Our findings suggest that a positive pre-SLO serum level of CA125 does not necessarily indicate tumor positivity. In addition, we suggest that the cut-off value for prediction of SLO findings should be below 35 U/ml, which is a commonly used cut-off value.     

Diagnosis and follow-up of ovarian cancer by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels

We used a combination assay of serum sialyl SSEA-1 antigen (SLX) and CA125 levels, and evaluated the clinical usefulness of this technique for a diagnosis of ovarian cancer and follow-up of the patient with ovarian cancer. In 28 patients with ovarian tumors, the sera of 8 (66.7%) of 12 with ovarian cancer and 5 (71.4%) of the 7 with endometriosis (endometrial cyst) were positive for both SLX and CA125, but serum SLX level was 50 U/ml or less in all these 5 SLX-and-CA125 positive patients with endometriosis. The sera of all 9 patients with benign ovarian tumor were negative for both tumor markers. No patient with endometriosis was negative for both markers. The diagnostic accuracy (true positive rate X true negative rate) of the combination assay for ovarian cancer was 50.3% when the cut-off value of the serum SLX was 38 U/ml but improved to 81.8% when the value was set at 50 U/ml. From the above observations, a combination assay of serum SLX and CA125 is promising method for the differential diagnosis of malignant and benign ovarian tumors. Our results also suggest that to improve the diagnostic accuracy, the cut-off value of the serum SLX level should be 50 U/ml for ovarian tumors alone. We found following-up two cases of ovarian cancer that the serum SLX level is not affected by the ascites and inflammation. We expect that this combination assay of serum SLX and serum CA125 will be beneficial for diagnosis and follow-up of ovarian cancer.     

Evaluation of serum CA 125 as a tumor marker in non-small cell lung cancer.

Serum CA 125 levels were evaluated in 130 healthy subjects and 133 patients with untreated pulmonary lesions. These were 33 patients with benign pulmonary conditions and 100 with lung cancer. The mean concentration of CA 125 was higher in patients with lung cancer (37 +/- 81 U/ml) than in those with nonmalignant disease (4.2 +/- 5.7 U/ml) (P less than 0.01). In the healthy control group CA 125 concentrations were significantly lower (0.63 +/- 1.5 U/ml) (P less than 0.001). In patients with lung cancer the concentration of this tumor marker was related to the tumor-node-metastasis (TNM) stage. At a cut-off value of 15 U/ml, CA 125 had a sensitivity of 44%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 65% with respect to healthy subjects; in patients with benign pulmonary conditions, these values were 44%, 94%, 94%, and 31%, respectively. At this cut-off value, a correlation between the respectability prognosis and the likelihood of survival 24 months posttreatment was observed. These findings suggest that CA 125 can be used as an adjunctive test in the management of patients with lung cancer patients.     

血清CA125测定对卵巢癌的诊断和治疗的意义

从１９８５年５月～１９８９年５月，作者采用单克隆抗体ＯＣ１２５，以放射免疫固相测定法进行检测人血清ＣＡ１２５抗原。测定结果，确定在本文研究中的血清ＣＡ１２５正常值为６５Ｕ／ｍｌ，≤６５Ｕ／ｍｌ为阴性，＞６５Ｕ／ｍｌ为阳性。卵巢上皮性癌患者的血清ＣＡ１２５水平８１．５％（７５／９２）为阳性，明显高于对照人群的２．５％，其中浆液性癌阳性率高达９３．２％（４１／４４）．根据ＣＡ１２５数值的动态变化来观察对评定疗效、预示复发及指导选择二探术等方面的临床意义，ＣＡ１２５阳性的病例不需要接受二探术，ＣＡ１２５水平与肿瘤变化的符合率达９２．９％。这充分证明ＣＡ１２５＞６５Ｕ／ｍｌ水平，肿瘤病灶＞２ｃｍ者，对化疗的反应差，预后也差。     

Clinical usefulness of serum and immunohistochemical markers in patients with stage Ia and Ic ovarian cancer

We compared the preoperative serum tumor marker values and diameters of ovarian tumors between 14 stage Ia ovarian cancer patients with a good prognosis and 14 stage Ic patients with a poor prognosis. The aim was to examine the usability of tumor markers and diameter of ovarian tumors for prognostic diagnosis of clinically advanced phases. In occult neoplastic cells (ONCs), a tumor marker indicative of recurrence and metastasis, the cytokeratin-positive cells in lymph node biopsies, were also compared. In a preoperative comparison of serum tumor markers, CA125 levels in stage Ia and Ic patients were 47.1+/-15.9 (median, 31.9 U/ml) and 370.6+/-146.2 U/ml (median, 135.6 U/ml), respectively (p=0.0457), and CA19-9 levels were 25.5+/-5.5 (median, 20.4 U/ml) and 564.5+/-192.4 U/ml (median, 248.0 U/ml), respectively (p=0.0131). In a comparison of tumor diameters during surgery, diameters of stage Ia and Ic patients were 117.3+/-11.4 (median, 100.0 mm) and 182.0+/-29.2 mm (median, 145.0 mm), respectively (p=0.0457). ONCs were not detected in any stage Ia patients, but detected in 3 (30%) stage Ic patients. In conclusion, clinical progression was evaluated using CA125 and CA19-9 serum markers and tumor diameters in stage Ia and Ic patients, and demonstrated significant differences between stage. ONCs were only detected in the lymph nodes of stage Ic patients.     

Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer

The aims of this study were: to characterise and compare plasma concentrations of midkine (MDK) in normal healthy women with concentrations observed in women with ovarian cancer; and to establish and compare the performance of MDK with that of anterior gradient 2 protein (AGR2) and CA125 in the development of multi-analyte classification algorithms for ovarian cancer. Median plasma concentrations of immunoreactive MDK, AGR2 and CA125 were significantly greater in the case cohort (909 pg/ml, 765 pg/ml and 502 U/ml, respectively n = 46) than in the control cohort (383 pg/ml, 188 pg/ml and 13 U/ml, respectively n = 61) (p < 0.001). The area under the receiver operator characteristic curve (AUC) for MDK and AGR2 was not significantly different (0.734 ± 0.046 and 0.784 ± 0.049, respectively, mean ± SE) but were both significantly less than the AUC for CA125 (0.934 ± 0.030, p < 0.003). When subjected to stochastic gradient boosted logistic regression modelling, the AUC of the multi-analyte panel (MDK, AGR2 and CA125, 0.988 ± 0.010) was significantly greater than that of CA125 alone (0.934 ± 0.030, p = 0.035). The sensitivity and specificity of the multi-analyte algorithm were 95.2 and 97.7%, respectively. Within the study cohort, CA125 displayed a sensitivity and specificity of 87.0 and 94.6%, respectively. The data obtained in this study confirm that both MDK and AGR2 individually display utility as biomarkers for ovarian cancer and that in a multi-analyte panel significantly improve the diagnostic utility of CA125 in symptomatic women.     

Gallstones and gallbladder cancer-volume and weight of gallstones are associated with gallbladder cancer: a case-control study

BACKGROUND: Gallstones are considered the most important risk factor for gallbladder cancer. AIM: To identify differences in the number, weight, volume, and density of gallstones associated with chronic cholecystitis (CC), gallbladder dysplasia (GD), and gallbladder cancer (GBC). METHODS: A total of 125 cases were selected, of which 93 had gallstones associated with GBC and 31 had gallstones associated with GD. The controls were those with CC, matched by sex and age. The number, weight, volume, and density of these gallstones were examined in order to determine differences and relative cancer risk. RESULTS: Number: Multiple gallstones were present in over 76% of cases (GBC and GD) and controls (P = ns). The average number of multiple stones was 21 in GBC versus 14 in controls (P < 0.01). Weight: The average weight of the gallstones was 9.6 g in GBC versus 6.0 g in controls (P = 0.0004). The average weight in multiple stones over 10 g had strong association with GBC (P = 0.0006). Volume: The average volume was 11.7 and 6.48 ml in GBC and controls (P = 0.0002). Average volumes of 6, 8, and 10 ml had a relative cancer risk of 5, 7, and 11 times, respectively. Size: No differences were shown between GBC, GD, and controls. CONCLUSIONS: The volume of gallstones associated with other risk factors of GBC may be helpful in prioritizing cholecystectomies in symptomatic patients.     

Ca 125 Assay Used in Conjunction with Ca 15-3 and Tag-72 Assays for Discrimination Between Malignant and Non-Malignant Diseases of the Ovary

It has previously been suggested by the authors that elevated serum CA 125 levels may be of value in discriminating malignant from non-malignant pathologies among women with pelvic masses. Enhancement of this discrimination capacity might be achieved by utilizing additional serum assays. to test this hypothesis CA 125, CA 15-3 and TAG-72 levels were determined in double-blind fashion on 219 sera from patients undergoing diagnostic laparotomy for pelvic masses at six gynecological departments in the Stockholm area. Patient diagnoses were verified by chart review. of the 219 patients, 27 (12%) had non-mucinous ovarian carcinoma, of whom 26 (96%) had CA 125 levels of 35 U/ml or greater 23 (85%) had levels in excess of 65 U/ml. of 27 patients with mucinous or borderline ovarian carcinoma and patients with other malignancies 18 (67%) had CA 125 levels greater than 35 U/ml. of 165 women with non-malignant diagnoses 26 (16%) had CA 125 levels in excess of 35 U/ml and 8 (5%) greater than 65 U/mL Using reference values of 35 U/ml, 30 U/ml and 10 U/ml for the CA 125, CA 15-3 and TAG-72 assay respectively, only 3 of 165 (2%) of non-malignant patients were categorized as positive, compared to 23 of 27 (85%) of those with non-mucinous ovarian carcinoma. Moreover, an analysis of post-menopausal women revealed that the combination of assays—in a model controlling for the effect of CA 125—-increased the specificity for diagnosis of benign diseases in women with pelvic masses.     

非小细胞肺癌患者血清CA125水平与疾病进展时间的相关性

[目的]评价非小细胞肺癌(NSCLC)患者血清糖类抗原(CA125)水平与疾病进展时间(TTP)的关系。[方法]对中国中医科学院广安门医院2006年10月～2009年10月收治的154例非小细胞肺癌患者的血清CA125水平与疾病进展时间的相关性进行回顾性研究。[结果]血清CA125水平与临床分期相关,Ⅳ期患者血清CA125水平明显高于ⅢB期(P<0.05)。血清CA125水平≥123U/ml的患者半年内进展的风险比CA125水平<123U/ml的患者增加89%(OR=1.889,95%CI:1.254～2.845,P=0.002)。[结论]血清CA125水平与患者疾病进展时间有明显的相关性,可通过检测CA125水平判断患者预后。     

Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA

Recently, a new RIA method has been developed by Centocor Co., utilizing the monoclonal antibody CA 15-3. We performed a clinical trial to evaluate its utility as a tumor marker for breast cancer in comparison with CEA. We set 15 U/ml as the cut-off value of serum CA 15-3 level from results acquired from controls; 10 volunteers and 17 patients with non-malignant diseases. The CA 15-3 positive rate among the cases of primary breast cancer was 13.3%, which was of poor diagnostic value. In the recurrent cases the positive rate of CA 15-3 was 72.0%, which was valuable compared with that of serum CEA, 52.0%. In the cases of primary cancers other than breast cancer, the positive rate of CA 15-3 was 6.9%.     

Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions.

We evaluated the diagnostic utility of simultaneous determination of 5 tumor markers, CEA, CA 125, CA 15-3, CA 19-9 and cytokeratin 19 (CYFRA 21-1), in fluid and serum from 101 patients, 52 with pleural effusion (22 malignant) and 49 patients with ascites (14 malignant). Tumor marker concentrations in fluid from patients with malignant effusions were significantly higher than those obtained in benign fluids or serum. However, there are two types of tumor markers: those released/secreted by normal mesothelia such as CA 125 and cytokeratin 19 (higher levels in benign fluids than in serum) and non-released/secreted tumor markers (low concentrations in benign fluids) such as CEA, CA 19-9 and CA 15-3. The fluid/serum (F/S) ratio showed better sensitivity with maximum specificity than a single determination in fluid for CEA, CA 15-3 and CA 19-9, but not for CA 125 and CYFRA. The combination of a F/S ratio greater than 1.2 and a cut-off of 5 ng/ml for CEA, 30 U/ml for CA 15-3 and 37 U/ml for CA 19-9 showed sensitivities of 58, 57 and 44%, respectively, and a specificity of 100%, with a combined sensitivity of 82% for overall effusions and 79% for fluids with negative cytology with a specificity of 100%. In conclusion, the use of the F/S ratio in nonsecreted tumor markers such as CEA, CA 19-9 and CA 15-3 improve the sensitivity and specificity and allow standardization of the cut-off.     

血清CA153、CA125、CA199和CEA联合检测在乳腺癌诊断中的价值

目的探讨联合检测血清CA153、CA125、CA199和CEA的含量对乳腺癌的诊断价值。方法运用电化学发光免疫分析方法检测乳腺癌68例、乳腺良性疾病50例及体检健康女性58名血清中CA153、CA125、CA199、CEA的含量,分析各肿瘤标志物诊断的灵敏度、特异度、准确度及联合检测的临床意义。结果单独检测CA153、CA125、CA199、CEA对乳腺癌诊断的阳性率分别为76．4％（52／68）、44．1％（30／68）、35．3％（24／68）、29．4％（20／68）;联合检测4种肿瘤标志物的阳性率为94．1％（64／68）。结论血清CA153、CA125、CA199和CEA联合检测具有提高乳腺癌早期诊断的价值。